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 The National Institute of Health (NIH) has used the term “epidemic” 
to describe PTSD, with some 7.1 million Americans affected as of 2009.  
Presently, PTSD is generally treated through a combination of 
psychotherapy and psychopharmacological approaches; however, alternate 
approaches such as acupuncture, hypnotherapy, and hyperbaric oxygen 
therapy (HBOT) have also been inappreciably investigated.  Each type of 
PTSD treatment has varying effectiveness, side effects, and cost.  While 
many individual studies of specific treatments for PTSD are published, there 
is scarce information on the prevalence of use of treatment modalities for 
PTSD in current practice.  Measuring the distribution of the multiple PTSD 
treatment options would inform researchers, clinician, and most importantly 
patients on the frequency, benefits, and cost burden of current modalities 
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   A. Background and Need 
Post Traumatic Stress Disorder (PTSD) is a confounding mental health disorder 
because of its differences in symptom presentation and symptoms associated with other 
anxiety related conditions that have similar comorbid characteristics.  PTSD is a negative 
result of a severe adverse associative relationship between the receiver and a significant 
traumatic event.  According to the National Center for PTSD, 7 or 8 out of every 100 
people (or 7-8% of the US population) will have PTSD at some point in their lives.  
Additionally, about 8 million adults have PTSD during a given year (2016, May 22).  
Retrieved from http://www.ptsd.va.gov/public/PTSD-overview/basics/how-common-is-
ptsd.asp).  Its core symptoms comprise re-experiencing traumatic content, persistent 
avoidance of traumatic content, negative alterations in cognitions, and arousal and 
reactivity (American Psychiatric Association, 2013).  Re-experiencing the traumatic 
content can occur through multiple ideations to include flashbacks, audiovisual cues, and 
olfactory sensory perceptions to induce latent PTSD symptoms.  Conceptually, PTSD can 
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be considered as a maladaptation to a traumatic stressor, with altered fear-related learning 
(fear conditioning) and extinction, behavioral sensitization/kindling, and alterations in 
brain areas and neurotransmitters systems closely linked to these processes (Steckler & 
Risbrough, 2012).  Additionally, behavior associated with PTSD almost always involves 
the retreat from or avoidance of objects or events that incites hyperarousal due to the 
recollection of the traumatic event.  
PTSD generally continues for long periods, with a median time of recovery in the 
range of 3 to 5 years (Polak, Witteveen, Visser, Opmeer, Vulink, Figee, Denys, & Olff, 
2012).  Everyone will experience some type of traumatic event during the course of his or 
her life; however, the ability to cope with this event, return to normal functioning 
capacity, and the undiminished awareness of comprehending the events relationship to 
the nature of the human experience should be the aim of reducing the significant impact 
of trauma related experiences over time.  Under the revised fourth edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), PTSD was the 
third most common anxiety disorder in the United States for adults aged 18-64 years, 
with lifetime prevalence estimates below only those of specific phobia and social phobia 
(Bentkover, Aldern, Lerner, Richardson, Chadha, Jacques, & Bautista-Saeyan, 2015).  
Traumatic events that could potentially trigger PTSD episodes include sexual assault, 
rape, national disasters, major traffic accidents, sudden death of close family members, 
combat action, terrorism, and other significant emotional events where the threat of death 
or serious bodily injury is present.   
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Unsurprisingly, PTSD is a significant public health burden in the United States 
due to its prevalence.  This causal effect has resulted in varied and substantially different 
treatment options for patients clinically diagnosed with PTSD.  These variations are not 
only conspicuous in effective and favorable outcomes, but also in the cost burden 
associated with administering treatment.  A recent study determined substantial PTSD 
per-case direct costs of $19,407 for Medicaid patients and $11,287 for privately insured 
patients (Ivanova, Birnbaum, Chen, Duhig, Dayoub, Kantor, Schiller, & Phillips, 2011).  
While the cost effectiveness of PTSD treatment is not the primary focus of this study, it 
will inform researchers on the transparency of treatment costs analogous to treatment 
options and if the underlying center of gravity for treatment decisions in private practice 
are linked to reimbursable private insurance cost and the ability of the patient to pay for 
mental health services.   
PTSD is a highly heterogeneous disorder with a total of 79,794 unique symptom 
constellations described that meet the clinical threshold for PTSD diagnosis based on 
DSM-IV criteria (Smith, Summers, Dillon, & Cougle, 2016).  When examining PTSD in 
society, multiple studies have shown that women are at greater risk for developing PTSD 
than men in both civilian and military populations.  This dynamic is significant in that the 
nature of the traumatic event and its gender association with the increased risk of 
developing PTSD requires further examination.  Although gender differences exists in the 
type of traumatic events experienced (e.g. women are more likely to be victims of sexual 
assault) and the number of traumatic events experienced, neither of these provide an 
adequate explanation for the elevated risk for PTSD seen among women (Norr, Albanese, 
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Boffa, Short, & Schmidt, 2016).  This relationship further amplifies the need for 
mitigation strategies to combat and treat PTSD with a keen eye on those factors that have 
the greatest impact on improved gender specific outcomes.   
Men and women with PTSD experience a greater number of medical co 
morbidities than individuals without PTSD; it is possible that among patients with PTSD, 
those with medical co morbidities feel too overwhelmed by multiple health issues and or 
medical treatments to be interested in and/or seek psychological care for PTSD (Breland, 
Greenbaum, Zulman, & Rosen, 2015).  The bifurcation between the comorbidity 
paradigm and its relationship to PTSD is a key component to understanding this complex 
phenomenon.  Comorbidity is the norm rather than the exception, with approximately 80-
85% of chronic PTSD cases meeting the criteria for at least one other axis I condition.  
The most common co-morbid conditions are major depression, substance use disorders 
and other anxiety disorders (Creamer & O’Donnell, 2002).  
 Current research on PTSD has focused significantly on the effects of PTSD on the 
US military and veteran populations in light of the enormous amount media attention and 
scrutiny surrounding perceived mistreatment and adverse outcomes (increased suicides, 
domestic violence, and maladaptive transition to civilian life) as well as the social and 
economic impacts of military healthcare.  In 2012, the Department of Defense (DOD) 
spent $52 billion on health care for service members, retirees, and their families.  As a 
result, even as overall funding for defense increased sharply, health care funding as a 
share of those resources rose to almost 10 percent in 2012 (Congressional Budget Office, 
2014).  Federal agencies such as the DOD and the Veterans Health Administration 
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(VHA) have invested significantly in the awareness, prevention, and treatment of mental 
health disorders such as depression, traumatic brain injury (TBI) and other illnesses, 
which are significant contributors to the ballooning defense budget of the federal 
government.   
In terms of direct cost, the VHA spends $8,300 per case for the first year of PTSD 
specific treatment and $660 million in direct costs for four years of treatment (Ivanova et. 
al, 2011).  Those who serve in the military are at an even greater risk for PTSD regardless 
of gender due to the inherent nature and dangers of military service, particularly if their 
service involved deployment in combat zones where the threat and possibility of death 
are ever present.  It is well documented that after the September 2001 attacks on the 
United States and its subsequent military operations in the Middle East over the last 15 
years, the Department of Defense and the Department of Veterans Affairs have both 
struggled with providing effective diagnosis and treatment for PTSD and other pervasive 
mental health disorders among its active duty and veteran populations.  Anecdotal 
evidence suggests that this problem indirectly exacerbated the coincidental overlap of the 
suicide epidemic that has plagued the US military and veteran populations over the past 
10-12 years.   
Presently, PTSD is generally treated through a combination of psychotherapy and 
psychopharmacological approaches; however, alternate approaches such as acupuncture 
and hyperbaric oxygen therapy (HBOT) have also been inappreciably investigated.  
There continues to be considerable debate as to whether the latter treatments modalities 
provide statistically significant improvements in PTSD outcomes.  While HBOT therapy 
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has revealed modest improvements in the treatment of TBI and other neurobiological 
conditions, recent studies by the US military have found no appreciative correlation with 
using HBOT for PTSD therapy.  Both psychotherapy and psychopharmacological 
approaches have different categories of treatment that will be further analyzed in this 
study.  The following first-choice interventions are recommended by most or all-clinical 
practice guidelines: eye movement desensitization and reprocessing (EMDR), exposure 
therapy (ET), cognitive therapy (CT), cognitive restructuring therapy (CR), cognitive 
processing therapy (CPT), and trauma-focused cognitive behavioral therapy (TF-CBT) 
(Haagen, Smid, Knipscheer, & Kleber, 2015).   
Medication treatments can be effective in PTSD, acting to reduce its core 
symptoms, and should be considered as part of the treatment of this disorder.  Although 
there is also no clear evidence to show that any particular class of medication is more 
effective or better tolerated than any other, the greatest number of trials showing efficacy 
to date, as well as the largest, have been with the selective serotonin re-uptake inhibitors 
(SSRIs) (Stein, Ipser, Seedat, Sager, & Amos,  2006).  It is imperative that clinicians 
understand that their preference of treatment modalities have significant impacts on their 
patient populations.  Clinicians may make treatment selections based on their clinical 
training, research knowledge, clinical judgment, clinic restrictions, logistics (e.g., time, 





Problem Statement  
Each type of PTSD treatment has varying effectiveness, side effects, and cost.  
However, while many individual studies of specific treatments for PTSD are published, 
there is scarce information on the prevalence of use of treatment modalities for PTSD in 
current practice.  Measuring the distribution of the multiple PTSD treatment options 
would inform researchers, clinician, and most importantly patients on the frequency, 
benefits, and cost burden of current modalities currently in use in the United States.  
There are published guidelines for diagnosing and treating PTSD disorders, but greater 
transparency and awareness is needed on the preferred methods clinicians use to treat this 
problem.  
While evidence-based PTSD treatments guidelines are recommended, there is 
research that suggests that PTSD medications are routinely prescribed outside of current 
guidelines.  Clinicians currently have an incomplete set of guidelines for when CPT or 
prolonged exposure (PE) is more likely to be beneficial for a given patient (Raza & 
Holohan, 2015).  The decision on the optimal approach between psychotherapy, 
psychopharmalogical methods or a combination of both should be a mutual decision 
between the patient and the health provider.  It is acknowledged that patient participation 
could potentially be withdrawn if a severe episode of PTSD or another associated 
comorbid disorder is presented; however, patient participation decisions in treatment 
options are generally known to improve patient compliance and patient outcomes.  This 
discrepancy is also observed among veteran populations receiving treatment at VHA 
health centers.  There is evidence that non-guideline supported pharmacotherapy for 
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veterans with PTSD is frequently practiced and mental health clinicians provided a larger 
proportion of these prescriptions than other types of practitioners (Abrams, Lund, 
Bernardy, & Friedman, 2013).  These discrepancies indicate that there is further need for 
additional evaluation of the efficacy of combining both psychotherapy and medications 
as first line treatment options. 
What follows this introduction (Chapter 1) is a comprehensive evaluation of 
previously published literature in the field of PTSD regarding symptoms, diagnosis, 
treatment methods, prevention, and opinions regarding future research in this field.  In 
Chapter 3, the methods utilized to investigate the prevalence and mix of PTSD treatment 
options will be discussed.  In Chapter 4, we will present the results of the statistical 
analysis, and finally Chapter 5 will provide our conclusion, limitations of our study, and 










Study Objective  
The objective of this study is to begin to investigate and identify the current 
prevalence and mix of PTSD treatments in the United States.  We will describe current 
practice patterns for privately insured patients age 18 to 65 with a diagnosis of PTSD.  
This is the first known study to analyze and report on this data. 
Study Approach 
We will use the 2013 and 2014 Market Scan® data set to examine treatment mix 
observed in a cohort of US patients with at least one diagnosis of PTSD recorded in 2013.  
The time horizon for the study is one year after the index PTSD diagnosis (or until death 
if sooner than 12 months).  
Study Aims  
We will describe: 1) Treatment patterns, including frequency and type of therapy, 
drug treatment and other modalities; 2) Use of hospital, emergency department and 













Review of the Literature 
 A comprehensive review of the literature indicates that PTSD is a heavily 
researched and studied mental health disorder.  The electronic databases 
Ovid/MEDLINE, PubMed, ScienceDirect, and CINAHL were searched using multiple 
key words: PTSD, PTSD prevalence, PTSD causes, PTSD symptoms, PTSD treatment, 
PTSD outcomes, PTSD epidemiology, PTSD military, and PTSD trauma.  The National 
Institute of Health (NIH) has used the term “epidemic” to describe PTSD, with some 7.1 
million Americans affected as of 2009 (Church, Feinstein, Palmer-Hoffman, Stein, & 
Tranguch, 2014).  While there remains significant interest in PTSD and its effects on 
society, the current research trends continue to expand and focus on the significant 
burden PTSD has had on US military and veteran populations.  Most recent PTSD 
research continues to amplify the significant problems associated with properly 
identifying and diagnosing PTSD and its associated symptoms.  The issue of the 
standardization of PTSD guidelines and protocols for diagnosis and treatment remain 
elusive.  Current assessment tools ranging from guidelines from the World Health 
Organization (WHO) to the American Psychiatric Association’s (APA), Diagnostic and 
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Statistical Manual of Mental Disorders (DSM) have increased awareness and has helped 
to identify and characterize common symptoms and characteristics of PTSD.  In spite of 
this, there remains considerable variance in how PTSD is treated among physicians and 
other medical professionals in both inpatient and outpatient settings.   
Epidemiological studies indicate that approximately 15-25% of individuals 
experiencing a significant trauma will go on to develop PTSD, although approximately 
half will recover without formal intervention (Creamer & O’Donnell, 2002).  The APA’s 
DSM remains the current gold standard diagnostic tool for PTSD and other psychiatric 
disorders internationally and in United States.  However, it is not without critics who 
believe that it is too conforming to social norms and lacks validity due to a perceived lack 
of transparency of board and panel members who develop the diagnostic criteria and have 
personal connections to various pharmaceutical companies that manufacture medications 
for various psychological disorders.   
Other key areas of PTSD research centers on prevention, PTSD comorbidity, 
treatment modalities, and their resulting efficacy and overall clinical outcomes.  
Understanding the prevalence and pervasive qualities of this disorder is crucial in 
identifying persons at greater risk for developing PTSD.  Extant research has outlined 
several factors that complicate the documentation of accurate prevalence estimates and 
comparison of prevalence estimates of PTSD across studies.  These factors include 
employment of different diagnostic criteria assessment of lifetime versus past year PTSD, 
and the use of specific samples (Reynolds, Pietrzak, Mackenzie, Chou, & Sareen, 2016).   
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Estimates on the prevalence of PTSD vary depending on the population, the 
traumatic event, the diagnostic criteria used, and other methodological factors.  
Prevalence rates are also likely affected by issues related to PTSD course, chronicity, and 
comorbidity; symptom overlap with other psychiatric disorders; and sociopolitical and 
cultural factors that may vary over time and by nation (Richardson, Frueh, & Acierno, 
2010).  Reports of lifetime prevalence in community samples are usually around 5-10%, 
representing approximately 15-25% of those exposed to traumatic events, whereas the 
12-month prevalence rates vary between 1.3% and 3.9 % (Creamer & O’Donnell, 2002).  
Among military personnel, researchers approximate that the prevalence of PTSD among 
returning U.S. military service members is between 5% and 20 %, although some assert 
that the most reliable estimates fall between 10% and 14% (Fisher, 2014).  Persons who 
are treated in hospital emergency rooms and intensive are units (ICUs) were shown to 
have greater risk for developing PTSD.  Jackson et al. (2007) reported that PTSD 
prevalence rates varied from 5% to 63% for medical ICU patients (Jackson, et al., 2007). 
Several studies suggest that psychological characteristics, such as personality, are 
related to how individuals react against the occurrence of stressful situations, promoting 
PTSD in some cases.  Specifically, many personality disorders have been associated with 
PTSD diagnosis, such as avoidant, schizotypal, borderline, and narcissistic personality 
disorder (Reis, Carvalho, & Elhai, 2016).  While identifying the underlying cause 
remains elusive, there is general agreement that trauma is the common denominator and 
the catalyst that precipitates the posttraumatic episode.  With regard to trauma, severity of 
the trauma is also a key component of developing PTSD.  There is also an increased risk 
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of PTSD in people with occupations such as firefighting, law enforcement, and 
emergency medical services, and those experiencing a critical medical event, such as 
cancer survivors, cardiac arrest survivors, and mothers who have experienced perinatal 
death (Murphy, 2015). 
        Traumatic events generally associated with PTSD include experiencing man 
made or natural disasters, combat experience, terrorism, car accidents, severe trauma, 
sexual assault (including rape), and other events where death or serious injury is possible.  
PTSD is the most commonly studied and probably the most frequent and debilitating 
psychological disorder that occurs after traumatic events and disasters (Galea, Nandi, & 
Vlahov, 2005).  In the civilian population,  PTSD following motor vehicle accidents, the 
most common cause of PTSD, is less likely to be recognized by the general population 
and medical community than PTSD caused by exposure to military combat (Eovaldi & 
Zanetti, 2010).  Among military personnel and veterans, acceptance and 
acknowledgement of a PTSD diagnosis is often perceived as an indicator of weakness 
and goes unreported despite the significant burden it presents to the service member, their 
families, and their military organizations.  Fisher (2014) reported service members and 
veterans who display or admit symptoms of PTSD, or who receive a PTSD diagnosis, 
were perceived by interviewees to be discredited or devalued by their peers.  In the 
military community, the emotional toll and stigma associated with mental health 
conditions is one that is frequently discussed, but rarely studied in the context of its 
impact on military personnel and veterans and their reluctant to receive treatment for 
PTSD.   
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PTSD has been a recognized disorder in the APA’s Diagnostic and Statistical 
Manual for more than 30 years (Fisher, 2014).  PTSD was initially classified as an 
anxiety disorder with associated diagnostic criteria provided with guidance on specific 
symptoms.  These criteria included a gateway criterion (criterion A) which suggested that 
certain traumas were ‘‘eligible’’ traumas and that only these events were capable of 
producing PTSD.  The fifth revision (DSM-5) was released in May 2013.  This revision 
includes changes to the diagnostic criteria for PTSD and Acute Stress Disorder.  PTSD 
(as well as Acute Stress Disorder) moved from the class of anxiety disorders into a new 
class of "trauma and stressor-related disorders.”  The rationale for the creation of this new 
class is based upon clinical recognition of variable expressions of distress as a result of 
traumatic experience (2016, June 19).  Retrieved from 
http://www.ptsd.va.gov/professional/PTSD-overview/diagnostic_criteria_dsm-5.asp.  
DSM-5 criteria are a significant departure from the criteria recommend for PTSD 
guidelines issued in the DSM-IV version.  To minimize the impact on this conversion, 
Rosellini et al. (2015) showed that DSM –IV criteria can be used to closely approximate 
DSM-5 criteria to provide a principled basis for recoding DSM-IV diagnosis in 
previously collected research samples to generate estimates of DSM-5 PTSD. 
The diagnosis of PTSD may appear to be a comprehensive and straightforward 
process due to established DSM guidelines, but due to the divergent opinions of 
clinicians, their individual experiences, and evidence-based research, there remains great 
variance in the diagnosis and treatment preferences for PTSD.  While this is significant, 
there is less divergence on the defining presence of a traumatic event preceding a 
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posttraumatic episode.  The event must involve an experience of threat to one's physical 
well-being or witnessing (seeing, hearing about) the death, injury, or threat to physical 
well-being of another person.  In addition, the individual's subjective reaction must 
include but is not limited to the experience of fear, horror, and helplessness.  If the event 
and the individual's reaction fulfill such criteria, the diagnosis of PTSD can be considered 
(Charuvastra & Cloitre, 2008).   
The multivariate dimensions of PTSD coupled with the likely presence of 
symptoms for other co-occurring psychiatric conditions inhibits the accuracy of 
diagnosing PTSD as a singular psychiatric condition.  PTSD is highly comorbid (83–
90%) with other psychiatric disorders, including mood, substance use, personality, and 
panic disorder (Bradley, Greene, Russ, Dutra, & Westen, 2005).  For this reason, 
healthcare providers and researchers must consider a holistic approach when accurately 
diagnosing PTSD with a critical eye on understanding that other serious conditions may 
potentially affect the desired outcome for effective treatment of PTSD symptom while 
inversely affecting recovery from other comorbid conditions.  The co-occurrence of 
depression with PTSD is an area of significant interest to researchers due to its 
presentation and similarity of symptoms.  In a study conducted by Ronconi, et al., (2015), 
researchers found that existing PTSD treatments were as effective for comorbid 
depressive symptoms as they were for PTSD symptoms.  Therefore, the presence of 
associated depressive symptoms should not necessarily influence treatment choice.   
In another study, Papini et al., (2015) suggests that specific linguistic 
characteristics of non-trauma-related speech are linked to PTSD diagnosis and symptom 
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severity.  Specifically, a PTSD diagnosis among individuals with a trauma history was 
associated with greater use of third-person singular pronouns and death-related words, 
but decreased use of third-person plural pronouns.  To receive a diagnosis of PTSD, the 
symptoms must last more than one month in duration and must cause clinically 
significant distress or impairment (Brady, Tuerk, Back, Saladin, Waldrop, & Myrick, 
2009).  Since PTSD often presents similar comorbid symptoms as other behavior health 
conditions, this makes initial diagnosis challenging.  The overlap of symptoms requires 
detailed feedback from the patient, which necessitates a thorough examination of the 
patient’s history and recognition of past events, which may have induced PTSD based on 
the patient experience.  
Further complicating diagnosis, categorizing and associating the traumatic event 
is also a reoccurring problem.  Defining trauma has been controversial since DSM-III.  
Regardless of whether new subtypes or disorders are created, clinicians must recognize 
the various manifestations of trauma, so that simply managing symptoms does not 
distract from treating underlying causes (Guina, Welton, Broderick, Correll, & Peirson, 
2016).  Thus, accurately diagnosing PTSD is crucial for the application of appropriate 
treatment options for PTSD patients.  Patients are likely to experience anxiety, 
depression, and hopelessness when PTSD symptoms are unremitting and interfere with 
their cognitions, emotions, sleep, interpersonal relationships, and daily life demands 
(Haviland, Banta, Sonne, & Przekop, 2016). 
The core symptoms of PTSD include reexperiencing symptoms and intrusive 
thoughts, avoidance of traumatic stimuli, negative alterations in thoughts and moods, and 
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increased physiological arousal (including sleep and concentration difficulties) (Boyd, 
Rodgers, Aupperle, & Jak, 2016).  In most cases, PTSD symptoms remit over the first 
months after trauma, but for a minority of individuals, symptoms become persistent, 
often causing significant impairment in daily functioning (Morina, Wicherts, Lobbrecht, 
& Priebe, 2014).  The subtle variations in PTSD symptoms are such that they are easily 
misinterpreted or misdiagnosed with other anxiety disorders such as depression.  It was 
previously mentioned that PTSD is highly comorbid and as a result, untreated PTSD may 
have wider consequences for developing other serious medical conditions.  Current 
findings contribute to a broader literature demonstrating that PTSD is associated with an 
array of negative physical health outcomes, including cardiovascular diseases (e,g, 
hypertension and heart disease), respiratory diseases, gastrointestinal illness, and non 
headache-related chronic pain conditions, such as fibromyalgia, back pain, and arthritis 
(Pacella, Hruska, & Delahanty, 2016). 
PTSD symptoms present in many different ways.  There is an association between 
both physical and emotional symptoms, which are characteristic of the common PTSD 
profile.  Considerable debate remains concerning how PTSD is acquired.  A traumatic 
event is the catalyst, but the corresponding response and reaction are areas where 
researchers have differing opinions on whether PTSD is acquired or the result other 
environmental influences.  There may also be distinct personality traits that predict a 
higher risk for developing PTSD.  The research of Contractor et al., (2016) indicates that 
personality traits influence four aspects of PTSD symptoms: (1) vulnerability, (2) 
resilience, (3) posttraumic growth (PTG), and (4) behavioral expressions.    
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It must be stated that presentation of PTSD is as varied as each individual who 
suffers from this disorder.  Symptoms are also not always present immediately preceding 
the traumatic event.  Oftentimes symptoms are displayed inconsistently over a period of 
time, which could be weeks or months after the traumatic episode.  Research and 
evidence related to the pathogenesis of PTSD suggests that the dysfunction is not merely 
present in the mind, but that organic changes in the hippocampus and limbic system are 
also involved (Eovaldi & Zanetti, 2010).  This biological response contributes to the 
difficulty in properly diagnosing PTSD due to its impact on other areas of the body, not 
just the brain and other sensory organs.   
It is crucially important that clinicians and other providers who treat PTSD are 
cognizant of the different cultural profiles of patients suffering from PTSD symptoms.  A 
current study suggests that different racial, gender, and other sociodemographic variables 
influence symptom patterns among different groups.  Nevertheless, racial/ethnic and 
gender differences in PTSD symptom cluster presentation at treatment initiatio n indicate 
that the healthcare provider’s cultural competence may require a nuanced understanding 
of how symptoms of mental health disorders are experienced by individuals from diverse 
backgrounds, particularly for women, in order to better detect PTSD as early as possible 
(Koo, Hebenstreit, Madden, & Maguen, 2016).  The various views on mental health 
treatment are a possible key indicator of future treatment compliance and acceptance after 
diagnosis.   
 PTSD has proven itself notoriously difficult to treat effectively (Bradley, et al., 
2005).  This is due to numerous reasons, which include variations in the acceptance of 
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established clinical practice guidelines, patient compliance with prescribed treatment, 
disagreement on the effectiveness of specific psychotherapy techniques, and several other 
concerns generally related to physician experience and preference, which ultimately 
affect patient outcomes upon diagnosis.  The choice of treatment in common clinical 
practice is rather arbitrary and seems to partly depend on indirect and direct assumptions 
of the clinician, style of health service delivery, and patient factors (Polak, Witteveen, 
Visser, Opmeer, Vulink, Figee, Denys, & Olff, 2012).  A recent study revealed that 
physician experience is a major indicator of prescribing practice among health care 
professionals who treat PTSD symptoms.  Personal experience has a greater impact on 
psychological therapy prescription than professional characteristics whose findings 
suggest that educational efforts are required for decision-making skills regarding 
prescribing based upon evidence-based medicine rather than subjective factors (Verdoux, 
Cortaredona, Dumesnil, Sebbah, & Verger, 2014).   
  Once a positive diagnosis of PTSD has been made, collaboration between 
clinician and patient on a successful treatment program is often a major factor in 
ameliorating PTSD.  The vast majority (97.3 %) of people who screened positive of for 
PTSD wanted to be involved in treatment decisions.  Participants most commonly wanted 
information on treatment effectiveness, long-term benefits and side effects (Harick, 
Hundt, Bernardy, Norman, & Hamblen, 2016).  The introduction of pharmacological 
treatment for PTSD should be approached with special considerations by clinicians on the 
psyche of the patient.  If patients are not intimately involved in treatment decisions, the 
possibility of mistrust or denial of the severity of PTSD could surface.  During this 
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assessment phase of viable treatment options clinicians must be sensitive to patient 
perceptions of their diagnosis.  Labeling a patient as “complicated or “complex” has a 
potential iatrogenic effect of giving the patient the impression that “traditional 
treatments” will not be effective or that special or longer treatments are necessary 
(DeJongh et al., 2016).   
       A common question arises from patients when treating PTSD and other mental 
health disorders.  How long will the treatment last, and will it reoccur?  Researchers 
Schnurr and Lunney (2016) suggests that treating PTSD patients until the patient no 
longer meets diagnostic criteria results in optimal gains and good quality of life 
endpoints.  It is important to note that treatment gains for cognitive processing therapy 
(CPT) and prolonged exposure (PE) have been shown to maintain for five or more years 
post treatment (Resick, Williams, Suvak, Monson, & Gradus, 2012).  While there are 
multiple available options available to clinicians and patients, treatment for PTSD 
generally includes psychotherapy, medication, or a combination of both (Foa, 2006).  
Despite the aforementioned guidelines established by the APA, there continues to be 
much debate on the efficacy of the different treatment options.   
  Psychotherapy treatment retains high usage rates due to studies that show it has 
high response and acceptance rates by patients.  Patients diagnosed with PTSD were 
associated with both the greatest likelihood of receiving psychotherapy and with the 
largest dose of psychotherapy as measured by number of visits; this may be a result of 
ongoing reports of mixed results in randomized clinical trials on the effectiveness of 
pharmacological agents in the treatment of PTSD (Harpaz-Rotem, Libby, & Rosenheck, 
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2012).  Of patients who complete psychotherapy treatment, 67% no longer meet criteria 
for PTSD, and of those who enter treatment (whether or not they complete), the recovery 
rate is 56% (Bradley, Greene, Russ, Dutra, & Westen, 2005). 
 Within the psychotherapy treatment family, CBT, exposure therapy, cognitive 
restructuring, and eye movement desensitization and reprocessing (EMDR) have been 
shown to be clinically effective in treating PTSD.  Response rates for CBT’s are 
relatively high, with 50% to 80% of completers reporting significant symptom reduction 
(Schottenbauer, Glass, Arnkoff, Tendick, & Gray, 2008).  In their study, (Tuerk et al., 
2013), prolonged exposure (PE) was well tolerated by patients with PTSD, 73% of those 
who began treatment met criteria as treatment completers.  Treatment was also associated 
with large statistically significant and meaningful declines in the need for mental health 
services, with approximately a 30% reduction in annual mental health service utilization 
and associated costs of care and a 45% reduction for treatment completers.  Eye 
Movement Desensitization and Reprocessing (EMDR) was proposed as a psychological 
trauma treatment approach in 1987.  A study conducted by Chen et al., suggests that 
EMDR is slightly superior to CBT for treating adult PTSD (Chen, Zhang, Hu, & Liang, 
2015).  Treatment with EMDR was followed by significant reductions in PTSD, 
depression, and anxiety symptoms.  EMDR desensitization was also followed by 
significant decreases in the distress and vividness associated with traumatic memories 
(Schubert et al., 2016).   
Based on high evidence-based response rates for psychotherapy, it is reasonable 
to conclude that these treatments will continue to be used to treat PTSD in the near 
22 
 
future; nevertheless, there are aspects of psychotherapy that may prevent preferred 
treatment outcomes due the extensive time require to complete treatment.  CBT is 
generally a time-limited treatment, with new skills practiced after treatment ends; one is 
not expected to continue in therapy for several years (Weisberg, Beard, Moitra, Dyck, & 
Keller, 2014).  
Similar to psychotherapy, there remains considerable debate as to when 
medications should be introduced when treating PTSD.  Therefore, a provider must make 
medication choices only after eliciting the patient’s feelings about being on medications 
and what meaning the patient places on taking psychiatric medications (Watson, Ghani, 
& Correll, 2016).  A recent study suggests that medications should be considered for 
initial PTSD treatment.  Boehnlein and Kinzie (2007) cite the Consensus Statement on 
Posttraumatic Stress Disorder for the International Consensus Group on Depression and 
Anxiety, which recommended SSRIs as first line treatment for PTSD.  While studies of 
PTSD patients have become increasingly sophisticated, clinical studies remain limited in 
their ability to probe the underlying neurobiology of PTSD.  Effective pharmacotherapies 
for PTSD are quite limited.  They include mainly selective serotonin reuptake inhibitors 
(SSRIs), with the only two FDA approved agents being paroxetine and sertraline (Perrine 
et al., 2016).  Benzodiazepines are used to treat some anxiety disorders and are indicated 
in some studies as successfully reducing comorbid PTSD symptoms; however, their 
effectiveness against approved SSRIs is not a focus of this study.  
 Since PTSD is a chronic illness, and the treatment selected is likely to be 
continued over an extended period, factors such as short- and long-term side-effect 
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profiles and the risks for drug/drug interactions are weighed strongly in deciding whether 
and at what point in treatment to include a medication (Bajor, Ticlea, & Osser, 2011).  As 
PTSD treatment has evolved, other novel and alternative treatment approaches have been 
researched which are gaining greater attention among researchers and clinicians.  Eovaldi 
& Zanetti (2010) suggests that hyperbaric oxygen therapy was effective in improving 
their patient’s acute psychiatric disturbance by effectively counteracting the pathological 
processes of oxidative stress, acute inflammation, vasogenic edema and hippocampal 
neuronal apoptosis.  Acupuncture has also shown appreciable efficacy.  A randomized 
controlled pilot trial conducted by Hollifield et al., (2007) indicates that acupuncture may 
be efficacious for reducing symptoms of PTSD, depression, anxiety, and impairment in 
people diagnosed with PTSD.  Acupuncture provided treatment effects similar to a group 
CBT intervention, and both interventions were superior to a wait-list control condition for 
all outcome measures (Hollifield, Sinclair-Lian, Warner, & Hammerschlag, 2007).  In 
their research, Church et al., (2014) also support acupuncture but state that nothing in the 
training or background of most physicians or researchers prepares them to understand 
how acupressure can play a role in overcoming severe psychological disorders or account 
for the speed and power of positive clinical results.  Another recent study champions the 
use of hypnotherapeutic techniques to treat PTSD.  In their study, O’Toole et al., (2016) 
reports significantly reduced PTSD symptoms, regardless of the time since the trauma 
occurred and whether it was witnessed, directly experienced, or both when 
hypnotherapeutic techniques were applied.  These studies further show that while 
psychotherapy and medications are the most frequently used treatment modalities for 
PTSD, other approaches with less invasive side effects are being considered. 
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It is impossible to discuss PTSD without mentioning its comorbid relationship 
with other psychiatric, biological, and physiological conditions.  In a study among 
veterans with PTSD in primary care, 87% have one or more comorbid psychiatric 
disorder, the most common being depression (Hollifield, 2011).  The phenomenon 
exacerbates the difficult nature of diagnosing and treating PTSD across treatment 
populations.  Zatzick et al. (2016) cites studies which show that multiple chronic 
conditions appear to endemic among physical trauma survivors treated in US trauma care 
systems (Mackenzie et al., 2006; Zatzick et al., 2007; Zatzick et al., 2015).  Patients being 
treated for multiple medical conditions are often incapacitated by the burden of dealing 
with multiple medical conditions simultaneously.  It is possible that among patients with 
PTSD, those with medical co morbidities feel too overwhelmed by multiple health issues 
and/or medical treatments to be interested in and/or seek psychological care for PTSD-
patients with numerous co morbidities often describe feeling burdened by managing 
multiple conditions (Breland, Greenbaum, Zulman, & Rosen, 2015). 
Patients with comorbid medical conditions that have adequate social support are 
more likely to have positive outcomes, whereas those who do not have adequate support 
are more prone to not adhere to directives, which may support improved and measurable 
treatment benefits.  Patients with strong support bases are more resilient and the success 
of family and couple-based treatment for PTSD in improving these cognitions is 
encouraging and provides support for the use of cognitive interventions in the dyadic 
treatment of PTSD (MacDonald, Pukay-Martin, Wagner, Fredman, & Monson, 2016).  
Based on research published thus far, it is clear that PTSD treatment in outpatient settings 
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and associated decision-making processes surrounding preferred treatment patterns 
practice remain inconsistent and may contribute to underutilization of prescribed 
treatment guidelines.  
In summary, the findings from the current literature indicate that there remains 
significant variance among health care professional regarding the diagnosis and treatment 
of PTSD despite available and prescribed guidelines promulgated on evidence-based 
studies.  PTSD is a difficult and elusive disorder that continues to affect millions of 
Americans.  The estimated number of Americans receiving outpatient mental health 
treatment increased from approximately 16.1 million in 1998 to 23.3 million in 2007 
(Olfson & Marcus, 2010).  Despite the prevalence and impact of PTSD on society, 
controversy persists about the efficacy of combining psychotherapeutic and 
pharmacotherapy treatments (Sorsdahl et al., 2013).  Recent studies have indicated a 
marked departure from psychotherapy to psychopharmacological treatments.  Mojtabai & 
Olfson (2008) suggests this may be attributed to reimbursement policies, which favor 
brief medication management visits rather than psychotherapy and the introduction of 
newer psychotropic medications with fewer adverse effects.  If there is a direct 
correlation between reimbursement and treatment options based on private insurers, then 
PTSD patients who are privately insured must be informed so that responsible decisions 
are made in concert with their physician.  The level of ambition exerted to ensure timely 
reimbursement should also be commensurate to the most effective treatment for PTSD 
patients.   
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Evaluating prescribing patterns in different patient settings will enhance and 
increase greater visibility on current trends in a privately insured patient population.  The 
current study will investigate and identify the current variations of PTSD treatment in the 
United States.  We will describe: 1) Treatment patterns, including frequency and type of 
therapy, drug treatment and other modalities; 2) Use of hospital, emergency department 
and outpatient visits; 3) Cost of treatment received.  We will also describe current 
practice patterns for privately insured patients age 18 to 65 with a diagnosis of PTSD.  
The primary aim of this study is to inform researcher and clinicians involved in PTSD 
research about current treatment variations of PTSD in a privately insured patient 









PTSD is a significant public health burden in the United States due to its 
prevalence.  This causal effect has resulted in varied and substantially different treatment 
options for patients clinically diagnosed with PTSD.  These variations are well described 
for Medicaid patients (Ivanova, Birnbaum, Chen, Duhig, Dayoub, Kantor, Schiller, & 
Phillips, 2011), but treatment patterns for privately insured patients who face economic 
barriers to care, such as co-insurance and deductible payments have not been described.   
The objective of this study is to describe the current prevalence and mix of 
treatments in the United States for privately insured patients.  This is the first known 
study to analyze and report on these data. 
Population  
Privately insured patients age 18 to 65 with a diagnosis of PTSD and insurance 
coverage for at least 12 months during 2013-2014, or until death (if death occurs before 
365 days) will be included in the study.  Inclusion criteria for the study are the presence 
of one or more inpatient or outpatient records with a diagnosis code for PTSD defined by 
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ICD-9 code.  Both male and female patients will be included.  All races will be included 
by default but subgroup analysis by race cannot be ascertained because commercial 
insurers in the US do not record patients’ race on their demographic records. 
Study Design and Data Source 
The design of the study is a retrospective analysis of archival billing data 
extracted from the 2013 and 2014 Market Scan® data set licensed to The Medical 
University of South Carolina (MUSC) by Truven.  The cohort chosen represent a cross 
sectional selection of privately insured patients with PTSD.  
Dataset Construction 
We will extract all records of patient with any PTSD code on inpatient or 
outpatient contacts during 2013.  The first occurrence will be designated as the Index 
Date of the study.  All records for the patient for 360 days post the Index Date or until 
death will be extracted from inpatient outpatient and prescription bills.  Records will be 
classified as 1) Therapy visits based on the Current Procedural Terminology (CPT) code 
or as 2) drug therapies based on their recorded National Drug Codes (NDC).  Within the 
two treatment groups, we will identify subtypes based on code details.  The detailed 
subgroup treatment classification scheme is provided in Table 1 below.  Therapy visits 
and drug therapy coverage days will be aggregated at the patient level.  Total cost for all 
medical care received will be calculated by summing all payments for the patient over the 




Data Analysis  
We will describe: 1) Treatment patterns, including frequency and type of therapy, 
drug treatment and other modalities using frequencies means and modes; 2) medical care 
utilization will be captured as the number of hospital, emergency department and 
outpatient visits and total days in the hospital; 3) Cost of treatment received will be 
summed within treatment group; and 4) Total annual cost of care will be calculated as the 
sum of all paid bills over the time of the study. 
Descriptive statistics will be used to compare hospital and other medical care 
utilization across the major treatment modalities.  Multivariable regression will be used to 
examine the contribution of the treatment modalities used to total cost over the study 
year.  Transformation of the data will be performed if needed to fit the assumptions 
underlying the statistical approaches used.  However, the purpose of the study is 
descriptive and we will use tables and graphic displays as much as possible to display 
variations in the data. 
Study Limitations 
The design of the study is cross sectional.  This approach has the advantage that it 
includes patients at all stages of PTSD.  However, it also has the disadvantage that it does 
not allow us to identify effect of time post injury on treatments.  In addition, we use 
archival billing data with ICD-9 to select patients with PTSD.  This approach is open to 
coding errors.  Further, we rely on CPT codes to identify therapy type, which may be 
subject to “up-coding” to increase reimbursement.  In addition, the drug therapy is 
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measured by dispensed prescriptions.  We do not know if the patient took the medication 
as prescribed.  
Table 1: Definition of PTSD and CPT and NDC Codes Used to Define Treatments. 
Variable Code Numbers Code Type  
PTSD 309.81 ICD-9  
Therapy Treatments:  CPT  
Cognitive-behavioral therapy (CBT) — 
involves working with cognitions to 
change emotions, thoughts, and 
behaviors. Types of CBT include 
exposure therapy, breathing retraining, 
biofeedback, cognitive restructuring, 






Psychotherapy — focuses on the 

















Hypnotherapy 90880   
Drug therapy: antidepressants to reduce 
depression and antianxiety medications 
to decrease sleep problems. 
Generic Drug Class 
Code 
  
Paroxetine  NDC  
Sertraline  NDC  










The objective of this study was to describe the current prevalence and mix of 
treatments in the United States for privately insured patients using data extracted from the 
MarketScan® data based licensed by Truven Analytics to the Medical University of 
South Carolina. 
Population  
A total of 6,819 privately insured patients age 18 to 65 with a diagnosis of PTSD 
and insurance coverage for at least 12 months during 2013-2014, or until death (if death 
occurs before 365 days) were included in the study.  Mean patient age was 42.6 years, 
distributed fairly evenly across four age categories.  There were slightly more patients in 
the youngest age group (18-34 years), and slightly fewer patients in the oldest group (55-
64 years) (p<.0001).   Three quarters of patients were female and one third were living in 
the Northeastern US, 18% each were living in the North Central and Southern US, and 
28%were living in Western states.  A total of 64 (0.9%) patients died during the 365-day 
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study period.  Racial distribution could not be examined because race is not available on 
these data.  Patient demographic characteristics are provided in Table 2 below. 
Table 2: Distribution of Age, Sex and Other Characteristics Among Study Patients 
Patient Characteristics Mean (SD) or Number (%) Statistic 
Age 42.6 (12.4)  
Age Group 18-34 1868 (27.4) P<.0001 
Age Group 35-44 1670 (24.5)  
Age Group 45-54 1931 (28.3)  
Age Group 55-64 1351 (19.8)  
Male 1588 (23.3) P<.0001 
Female 5231 (76.7)  
Died During Study 64 (0.9)  
Mean Days in Study 360.3 (20.6)  
Region: North East 2235 (32.8) P<.0001 
North Central 1205 (17.7)  
South 1254 (18.4)  
West 1954 (28.7)  
Unknown 171 (2.5)  
 
Treatments Received 
The main objective of this study was to describe the current prevalence and mix 
of treatments in the United States for privately insured patients.  Ninety percent of the 
patients with PTSD received psychotherapy with 15 percent of these patients also 
receiving either sertraline or paroxetine therapy.  An additional 119 (11.6%) of patient 
received sertraline or paroxetine but no psychotherapy, while 544 (8.0%) received no 
psychotherapy, sertraline or paroxetine.  The detailed findings are provided in Table 3 
below.  It is important to note that 90.3% of patients who received psychotherapy, on 
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average, had 28.5 treatment visits.  Sertraline was prescribed nearly 10 times as much as 
paroxetine, but had slightly lower mean daily drug doses at 204.5 days versus 232.4 days 
respectively.  Benzodiazepine (29.6%) and other anti-anxiety medications (48.7%) were 
most often prescribed than the SSRIs sertraline (12%) and paroxetine (2.8%).  This 
finding supports previous research, which indicates that PTSD is highly comorbid with 
depression and other anxiety disorders and diagnosing and treating PTSD in the presence 
of other co-occurring disorders with similar symptoms is extremely difficult and time 
consuming for both provider and patient.  Comparatively, of the alternative PTSD 
treatment options (acupuncture, hypnosis, and rTMS) acupuncture was the most 
frequently used PTSD treatment with 3.1% of patients receiving the treatment with an 
average of 24.4 visits over a year.  Hypnosis was the least utilized treatment option in this 
study with only 4 patients receiving this treatment over the course on 1 visit on average. 
Table 3: Treatments Received by PTSD Patients Over the Study Year 
Variable Name Number and Percent with 
Treatment 
Mean (SD) of Daily Drug 
Doses or Visits for 
Treatment for Patients 
Receiving Any 
Psychotherapy 6156 (90.3) 28.5 (27) 
Paroxetine 194 (2.8) 232.4 (139) 
Sertraline 839 (12.3) 204.5 (134) 
Acupuncture 208 (3.1) 24.4 (33) 
Hypnosis 4 (0.06) 1 (0) 
Benzodiazepine 2016 (29.6) 148.9 (149) 
Other Antidepressants 3332 (48.7) 336.1 (243) 




We examined the medical care utilization and total medical care cost for our 
patient group.  We enumerated the number of hospital and emergency department visits 
used by patients over the study year and calculated total cost for all medical care received 
by summing all payments for the patient over the 365 days in the study or until death if 
sooner than 12 months.  The average annual cost burden for each PTSD patient in the 
study was $18,862.  Of the 886 patient who had a hospital admission, they averaged 1.6 
admissions over the course of a year.  It is important to note that PTSD patients required 
an average of 38 office visits during the study time period.  Our medical care resource 
use findings and costs are provided in Table 4 below. 
Table 4: Annual Frequency of Emergency Department Visits, Hospital Admissions and  
Office Visits and Total Cost of Care for Patients with PTSD 
Medical Care Utilization Number and Percent of 
Patients Using the Type of 
Care 
 
Mean Use for Patients 
With Any Use of Type of 
Care 
Hospital Admissions 886 (13.0) 1.6 (1.3) 
ED Visits 1913 (28.1) 2.2 (3.7) 
Office Visits 6819 (100.0) 38.0 (29.0) 
Total Cost of Care $1,105,555  (100.0) $18,862 (37,451) 
 
 We also examined the total cost of medical care for PTSD patient subgroups. The 
highest total cost of treatment were for those patients who died during the study at a cost 
of $36,297 per patient.  Patients treated with SSRI medications had higher treatment costs 
at $25,197 per patient than those patients who received therapy only at $18,270 per 
patient.  Patients receiving therapy and SSRIs had slightly higher per patient costs at 
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$19,918.  Patients’ not receiving therapy or SSRI for alternative PTSD treatment had 
total treatment costs of $21,436 during the study period.  
 
Table 5: Total Cost of Medical Care for PTSD Patient Subgroups 
Patient Group Number (%) Total Annual Cost SD 
All Patients 6819 (100) $18,862 $37,451 
Surviving patients 6755 (99) $18,697 $36,427 
Patients who died 64 (1) $36,297 $96,033 
Patient receiving 
therapy only 
5251 (77) $18,270 $36,333 
Patients receiving 
therapy and SSRIs 
905 (13) $19,918 $34,010 
Patients receiving 
SSRIs only 
119 (2) $25,197 $50,021 
Patients not 
receiving therapy or 
SSRI 
544 (8) $21,436 $48,555 
 
 Primary diagnosis and cause of death of the 64 PTSD patient who died during the 
study yielded important observations. Of the PTSD patients, 30% of died from 
septicemia, pneumonia, HIV or other infections. 14% died from acute respiratory 
distress, renal failure, overdose or other poisoning.  Cancer was the next highest cause of 
death at 13% followed by other medical conditions which were significantly less 





Table 6: Primary Diagnosis for Hospital Admission for 64 PTSD Patients Who Died  
During the Study Period 
Diagnostic Groupings Number (%) 
Septicemia, pneumonia, HIV or other 
infection 
19 (30) 
Cancer 8 (13) 
Acute respiratory or renal failure 9 (14) 
Complications of transplant or medical 
procedure 
3 (5) 
Stroke or heart failure 4 (6) 
GI or metabolic problem 5 (8) 
Bipolar or Mood Disorder 3 (5) 
Head fracture or other injury 4 (6) 



















 Our primary objective was to identify which PTSD treatment methods were 
preferred based on current treatments options available to health care providers who treat 
PTSD patients.  This study provides valuable insight and has a number of important 
findings.  First, privately insured PTSD patients are treated using a variety of available 
PTSD treatment options.  Second, psychotherapy is the preferred method of treatment 
among clinicians who are reimbursed by private insurers.  Third, of the PTSD patients 
who are prescribed medications, anti-anxiety medications are most predominately 
prescribed rather than SSRIs and lastly, nearly 3 out of 4 PTSD patients in this study 
were women and most were treated for other co-occurring anxiety conditions.  
 To begin with, PTSD patients in the present study, were treated with numerous 
PTSD treatment options which include psychotherapy, psychopharmacological and 
alternative treatment approaches.  In our study 90% of the sample (n=6819) received 
some form of psychotherapy.  Although it is unclear what method of psychotherapy was 
used (ET, CBT, EMDR, etc.), it does suggest acceptance of and adherence to current 
38 
 
APA DSM guidelines, which recommend psychotherapy as the first line treatment for 
PTSD.  The minimal use of alternative approaches such as hypnotherapy (.06%), 
acupuncture (3.05%) and repetitive transcranial magnetic stimulation (.07%) to treat 
PTSD patients may indicate several important observations.  It informs clinicians that 
additional research and random controlled trial studies are necessary to prove that these 
methods as efficacious treatment options for PTSD, or it may suggest that there are not 
enough clinicians properly trained in these treatment approaches.  It could also be that 
patients are not comfortable with these methods, which are not mainstream treatments, 
which may be viewed as socially non-acceptable.  Risk adverse clinicians may also shun 
alternative approaches due to concerns about treatments that could affect patient safety 
with potential negative outcomes.     
 Within respect to service utilization, 13% of PTSD patients in this study were 
admitted to a hospital and 28% patients were treated in an ER.  These small percentages 
may be indicative of acute and unpredictable PTSD episodes before or after the initial 
PTSD diagnosis.  While this was not a key objective of the study, there could be 
variations across the primary and specialty care utilization rates with respect to 
prescribing frequency for those patients who were prescribed medications to treat PTSD 
symptoms.  Despite several studies promoting the efficacy of both psychotherapy and 
psychopharmacological approaches, there remains considerably debate over their 
acceptability, efficacy, and affordability for PTSD patients.  Considering the severity of 
their PTSD symptoms, appropriate and relevant decisions must be made and a variety of 
factors such as patient treatment preference, patient social support structure, duration of 
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PTSD treatment, and the experience and expertise of the clinician are all important things 
to consider.   
 An important observation was the disproportionate number of women versus men 
amongst the study population.  In this study, women comprised 76.7% of the population.  
While women are at higher risk for developing PTSD and they experience different types 
of trauma than men, this number may indicate that women are more likely to seek 
treatment for PTSD than men or are predisposed to other mental health conditions with 
comorbid PTSD present.  This would also explain the high number of anti-anxiety 
medications that were prescribed for those patients who were on medications such as 
benzodiazepine and other antidepressants.   
Limitations  
 The study has several limitations that must be considered when interpreting these 
findings.  First, the study is a concise review of PTSD diagnosis and treatment patterns in 
a privately insured cohort over the course of 1 year.  This is a very short period in which 
to evaluate the multiple factors that affect PTSD treatment.  Patients who are predisposed 
to certain treatments may not be receptive to the addition or subtraction of other possible 
efficacious treatment options.  Second, this study did not evaluate treatment outcomes to 
assess which PTSD treatment methods were most beneficial for patients based on cost, 
time burden, and possible side effects.  While psychotherapy was the preferred method of 
treatment in this study, the method of available psychotherapeutic treatment techniques 
was not observed.  This is significant in that some approaches such as CBT require a 
significant amount of time to produce tangible results.  Psychotherapy treatments can last 
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from a few 60-minute sessions to several weeks depending on the severity of PTSD.  This 
requires a significant time commitment in order to gain benefits from the treatment.  This 
study was not able to identify if this time burden had an impact on patient treatment 
outcomes.  
 Third, the high comorbidity rate of PTSD is another area in which this study did 
not purposely focus on, but has major implications in future research on PTSD diagnosis 
and treatment.  This area is contentious in that it must be decided which disorder is the 
primary focus of treatment or will there be a multidisciplinary approach to treating 
multiple psychiatric disorders simultaneously.  This is important, and has second and 
third order implications, which could ultimately determine whether there will be a 
successful PTSD outcome.  In addition, if medications are prescribed, clinicians must 
ensure that side effects do not have an adverse impact on PTSD treatments and on co-
occurring disorders such as depression, substance abuse, and other anxiety disorders.  
These findings also highlight the need for additional research on the efficacy of 
combining both psychotherapy and psychopharmalogical approaches in the treatment of 
PTSD.   
Fourth, in addition, we use archival billing data with ICD-9 to select patients with 
PTSD.  This approach is open to human coding errors.  Further, we rely on CPT codes to 
identify therapy type, which may be subject to “up-coding” to increase reimbursement.  
Lastly, the drug therapy is measured by dispensed prescriptions.  We do not know if the 
patient took the medication as prescribed and as previously discussed, we do not know 
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the treatment outcomes for any of the patients regardless of treatment plan directed by 
their clinician.  
Areas for Further Study 
 In conclusion, we assess that further research regarding treatment outcomes, cost 
and time burden on PTSD patients, and the efficacy of combining available PTSD 
treatment options in order to capitalize on this significant public health burden to both US 
civilian and military personnel who suffer from this debilitating disorder.  We hope that 
this study encourages further investigation into informing PTSD patients and clinicians 




























Table 7: Alphabetic List of Variables and Attributes             
 
AGE Age of Patient 
AGEGRP Age Group 
Accu Acupuncture 
AnyAccu Any Acupuncture 
AnyER Any ER Visit 
AnyHypno Any Hypnotherapy 
AnyIP Any Inpatient 
AnyPsyc Any Psychotherapy 
AnyTMS Any Transcranial Magnetic Stimulation 
Benzo Benzodiazepine 
BenzoDys Benzodiazepine Days Supply 
DaysPost Days Post Diagnosis 
Died Number of Patients Who Died  
ENROLID Enrollee ID 
ER_Tot Payment Total ER Visit 
ER_Vis Number of Emergency Room Visits 
HypTx Number of Hypnotherapy Treatments 
IP_Dys Number of Inpatient Days Length of Stay 
IndexDT Index PTSD Diagnosis 
Ip_Pay Number of Inpatient Payments 
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OP_Pay Number of Outpatient Payments 
OfficeVis Number of Office Visits 
Office_Tot Number of Office Payment 
OthAD Other Antidepressants 
OthADDys Other Antidepressants Days Supply 
PTSD Number PTSD 
Par Number on Paroxetine    
ParDys Paroxetine Number of  Days Supply  
PsyTx Psychotherapy Number of  Days 
REGION Region 
RxNum Prescription Number      
SEX Gender of Patient 
Sert Number on Serotonin 
SertDys Serotonin Number of  Days Supply 
TMS Number on Transcranial Magnetic Stimulation 
TotAdms Number of Total Admissions 
TotRxPay Number of Total Prescription Payments 
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